Vaccine Against Sexually Transmitted Diseases

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "HIV Vaccines".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 766

Special Issue Editor


E-Mail Website
Guest Editor
1. Institute for Global Health and Infectious Diseases, University of North Carolina at Chaple Hill, Chapel Hill, NC 27599, USA
2. Institute for Global Health and Sexually Transmitted Diseases, Southern Medical University, Guangzhou 510315, China
Interests: HIV; infectious diseases; infection; vaccination

Special Issue Information

Dear Colleagues,

This Special Issue, entitled "Vaccine Against Sexually Transmitted Diseases", of Vaccines highlights cutting-edge research and innovative strategies aimed at combating sexually transmitted infections (STIs) through vaccination. It features breakthroughs in vaccine development, targeting prevalent STIs such as human papillomavirus (HPV), HIV, syphilis, gonorrhea, and chlamydia.

This Special Issue emphasizes the importance of preventive measures, equitable access to vaccines, and the integration of vaccination programs into public health initiatives. By showcasing interdisciplinary collaborations and emerging technologies, this Special Issue aims to foster dialogue among researchers, clinicians, and policymakers to enhance global health outcomes and reduce the burden of STIs.

I look forward to receiving your contributions.

Dr. Weiming Tang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccination
  • sexually transmitted infections
  • HPV
  • HIV
  • syphilis, gonorrhea, and chlamydia
  • vaccine development
  • public health
  • epidemiology
  • health equity
  • preventive strategies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 524 KB  
Article
Correlates of Meningococcal B Vaccination and Health Behavior Profiles Among MSM in China
by Rongyan Li, Qian Zou, Yi Zhou, Ye Zhang, Dan Wu, Xinyuan Zhang, Fengshi Jing, Jie Fan, Xi He and Weiming Tang
Vaccines 2025, 13(9), 983; https://doi.org/10.3390/vaccines13090983 - 19 Sep 2025
Viewed by 270
Abstract
Background: Meningococcal B (MenB) vaccination offers protection against invasive meningococcal disease and moderate cross-protection against gonorrhea. However, little is known about coverage and behavioral correlates among men who have sex with men (MSM) in China. This study assessed self-reported MenB vaccination uptake and [...] Read more.
Background: Meningococcal B (MenB) vaccination offers protection against invasive meningococcal disease and moderate cross-protection against gonorrhea. However, little is known about coverage and behavioral correlates among men who have sex with men (MSM) in China. This study assessed self-reported MenB vaccination uptake and its associations with sociodemographic and behavioral factors. Methods: We conducted a nationwide cross-sectional survey among 1022 MSM recruited via community-based organizations and online platforms. Vaccination status and recent sexual behaviors were self-reported. Logistic regression identified correlates of uptake, and latent class analysis (LCA) examined behavioral profiles. Results: Participants had a mean age of 29.6 years; most were unmarried (87.7%) and nearly 90% had a college degree or above. Overall, 21.7% reported receiving MenB vaccination. Uptake was positively associated with condomless anal intercourse (aOR = 1.57, 95% CI: 1.08–2.31), group sex (occasionally: aOR = 1.63, 95% CI: 1.01–2.64; frequently: aOR = 3.86, 95% CI: 1.85–8.04), and female partners in the past six months (aOR = 3.69, 95% CI: 2.25–6.10). MSM with multiple casual male partners were less likely to be vaccinated (aOR = 0.55, 95% CI: 0.32–0.93). LCA identified heterogeneous subgroups; notably, the “multi-partner and proactive” group, with high pre-exposure prophylaxis against HIV infection awareness and frequent STI testing, showed low uptake (13.4%). Conclusions: MenB vaccination coverage among MSM in China remained suboptimal. Uptake differed across behavioral subgroups, underscoring the need for stratified, context-specific strategies to inform future vaccine introduction. Full article
(This article belongs to the Special Issue Vaccine Against Sexually Transmitted Diseases)
Show Figures

Figure 1

Back to TopTop